"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...
ATACAND HCT has been evaluated for safety in more than 2800 patients treated for hypertension. More than 750 of these patients were studied for at least six months and more than 500 patients were treated for at least one year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse events reported with ATACAND HCT was comparable to placebo. The overall frequency of adverse experiences was not related to dose, age, gender, or race.
In placebo-controlled trials that included 1089 patients treated with various combinations of candesartan cilexetil (doses of 2-32 mg) and hydrochlorothiazide (doses of 6.25-25 mg) and 592 patients treated with placebo, adverse events, whether or not attributed to treatment, occurring in greater than 2% of patients treated with ATACAND HCT and that were more frequent for ATACAND HCT than placebo were:
Respiratory System Disorder: upper respiratory tract infection (3.6% vs 3.0%); Body as a Whole: back pain (3.3% vs 2.4%); influenza-like symptoms (2.5% vs 1.9%); Central/Peripheral Nervous System: dizziness (2.9% vs 1.2%).
The following have been very rarely reported in post-marketing experience with candesartan cilexetil:
Digestive: Abnormal hepatic function and hepatitis.
Respiratory System Disorders: Cough
Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:
Hypersensitivity: anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, urticaria, purpura
Musculoskeletal: muscle spasm
Special Senses: transient blurred vision, xanthopsia
Read the Atacand HCT (candesartan cilexetil-hydrochlorothiazide) Side Effects Center for a complete guide to possible side effects
Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
Interactions common to both Candesartan Cilexetil and Hydrochlorothiazde
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors). In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy.
Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists or hydrochlorothiazide. Monitor serum lithium levels during concomitant use.
Interactions with Candesartan Cilexetil
Dual Blockade of the Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on ATACAND HCT and other agents that affect the RAS.
Interactions with Hydrochlorothiazide
Alcohol, barbiturates, or narcotics - Potentiation of orthostatic hypotension may occur.
Antidiabetic drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required.
Ion Exchange resins -Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Stagger the dosage of hydrochlorothiazide and ion exchange resins such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins.
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) -Possible increased responsiveness to muscle relaxants such as curare derivatives.
Read the Atacand HCT Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 2/20/2015
Additional Atacand HCT Information
Atacand HCT - User Reviews
Atacand HCT User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.